Dachaigh › Leukemia myeloid geur › Texas › Dallas
Sgrùdaidhean clionaigeach Leukemia myeloid geur ann an Dallas, TX
Tha 21 sgrùdaidhean airson Leukemia myeloid geur a’ lorg phàirtichean aig làraichean ann agus timcheall air Dallas (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
A’ fastadhÌre 1
- Children's Medical Center Dallas /ID# 275930, Dallas
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
A’ fastadhÌre 3
- Baylor University Medical Center, Dallas
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A’ fastadhÌre 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
A’ fastadhÌre 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
A’ fastadhÌre 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
A’ fastadhÌre 1/2
- Baylor Scott & White Health, Dallas
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
A’ fastadhÌre 3
- US-Dallas TX-SOUTHWESTERN, Dallas
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
A’ fastadhÌre 1/2
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
A’ fastadhÌre 3
- Harold C. Simmons Comprehensive Cancer Center, Dallas
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A’ fastadhÌre 3
- Texas Oncology-Presbyterian Cancer Center, Dallas
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A’ fastadhÌre 1
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
A’ fastadhÌre 1
- UT Southwestern/Simmons Cancer Center, Dallas
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
A’ fastadhÌre 3
- Baylor Charles A. Sammons Cancer Center, Dallas
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
A’ fastadhÌre 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A’ fastadhSgrùdadh amharc
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
A’ fastadhÌre 2
- UT Southwestern Medical Center at Dallas, Dallas
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A’ fastadhÌre 1
- UT Southwestern Medical Center, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
A’ fastadhÌre 1
- Baylor University Medical Center, Dallas
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
A’ fastadhÌre 2/3
- University of Texas Southwestern Medical Center, Dallas
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
A’ fastadhÌre 1
- UT Southwestern - Simmons Cancer Center, Dallas
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
A’ fastadhÌre 1
- University of Texas Southwestern Medical Center, Dallas
Sgrùdaidhean Leukemia myeloid geur ann am bailtean eile
- Houston, TX85 sgrùdaidhean
- New York City, NY51 sgrùdaidhean
- Boston, MA44 sgrùdaidhean
- Seattle, WA41 sgrùdaidhean
- Baldwin Park, CA40 sgrùdaidhean
- Columbus, OH35 sgrùdaidhean
- Philadelphia, PA34 sgrùdaidhean
- Durham, NC33 sgrùdaidhean
- Atlanta, GA31 sgrùdaidhean
- Tampa, FL29 sgrùdaidhean
- Chicago, IL26 sgrùdaidhean
- Portland, OR25 sgrùdaidhean
Sgrùdaidhean eile ann an Dallas
- Aillse a' bhroilleach55 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag52 sgrùdaidhean
- Ailse metastatach42 sgrùdaidhean
- Fàilligeadh a' Chridhe42 sgrùdaidhean
- Aillse (gach seòrsa)37 sgrùdaidhean
- Aillse Prostata36 sgrùdaidhean
- Aillse colorectal33 sgrùdaidhean
- Obesity30 sgrùdaidhean
- Cancer Ovarian28 sgrùdaidhean
- Ailseachadh nan Sgamhan27 sgrùdaidhean
- Aillse sa bhlaire27 sgrùdaidhean
- Ailse Endometrial24 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.